REGEN-COV is a Intravenous Injection, Solution, Concentrate in the Human Prescription Drug category. It is labeled and distributed by Regeneron Pharmaceuticals, Inc.. The primary component is Casirivimab; Imdevimab.
| Product ID | 61755-039_1b115152-c792-4dbd-aede-52dc7fdf8436 |
| NDC | 61755-039 |
| Product Type | Human Prescription Drug |
| Proprietary Name | REGEN-COV |
| Generic Name | Casirivimab And Imdevimab |
| Dosage Form | Injection, Solution, Concentrate |
| Route of Administration | INTRAVENOUS |
| Marketing Start Date | 2021-06-03 |
| Marketing Category | UNAPPROVED DRUG OTHER / |
| Labeler Name | Regeneron Pharmaceuticals, Inc. |
| Substance Name | CASIRIVIMAB; IMDEVIMAB |
| Active Ingredient Strength | 600 mg/10mL; mg/10mL |
| NDC Exclude Flag | N |
| Listing Certified Through | 2022-12-31 |
| Marketing Start Date | 2021-06-03 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 61755-035 | REGEN-COV | casirivimab and imdevimab |
| 61755-036 | REGEN-COV | casirivimab and imdevimab |
| 61755-037 | REGEN-COV | casirivimab and imdevimab |
| 61755-038 | REGEN-COV | casirivimab and imdevimab |
Mark Image Registration | Serial | Company Trademark Application Date |
|---|---|
![]() REGEN-COV 90284296 not registered Live/Pending |
Regeneron Pharmaceuticals, Inc. 2020-10-28 |